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Abstract
Myofibroblasts differentiate, invade and repair injured tissues by secreting and organizing the extracellular matrix
and by developing contractile forces. When tissues are damaged, tissue homeostasis must be re-established, and
repair mechanisms have to rapidly provide harmonious mechanical tissue organization, a process essentially
supported by (myo)fibroblasts. Under physiological conditions, the secretory and contractile activities of
myofibroblasts are terminated when the repair is complete (scar formation) but the functionality of the tissue is
only rarely perfectly restored. At the end of the normal repair process, myofibroblasts disappear by apoptosis but in
pathological situations, myofibroblasts likely remain leading to excessive scarring. Myofibroblasts originate from
different precursor cells, the major contribution being from local recruitment of connective tissue fibroblasts.
However, local mesenchymal stem cells, bone marrow-derived mesenchymal stem cells and cells derived from an
epithelial-mesenchymal transition process, may represent alternative sources of myofibroblasts when local
fibroblasts are not able to satisfy the requirement for these cells during repair. These diverse cell types probably
contribute to the appearance of myofibroblast subpopulations which show specific biological properties and which
are important to understand in order to develop new therapeutic strategies for treatment of fibrotic and scarring
diseases.
Introduction
Tissue repair is an essential phenomenon allowing tissues
and organs to recover functional properties that have
been lost after an injury, either linked to a wound or to a
disease. Contrary to what is seen in fetal or embryonic
wounds that repair without a scar or fibrosis, normal
repair in the adult always leads to scar formation, the
consequence of which may be defects in functionality
(e.g. skin hypertrophic scar or fibrosis). In these pro-
cesses, fibroblasts/myofibroblats play a crucial role.
Moreover, myofibroblasts are instrumental in the stroma
reaction to epithelial tumors and are now thought to pro-
mote cancer progression by creating a stimulating micro-
environment for the transformed cells [1,2].
The myofibroblast in normal and pathological
situations
Normal wound healing
Immediately after wounding, the healing process allowing
restoration of injured tissue occurs. Wound healing pro-
ceeds in three interrelated dynamic phases with overlap-
ping time courses. According to morphological changes
in the course of the healing process, these phases are
described as an inflammatory phase, a proliferative phase
for the development of granulation tissue, and a regen-
eration phase for maturation, scar formation and re-
epithelialisation [3]. The inflammatory phase begins with
damage to the capillaries, which triggers the formation of
a blood clot consisting of fibrin and fibronectin. This
provisional matrix will fill in the lesion and will allow the
various recruited cells to migrate into wound. Platelets
present in the blood clot release multiple chemokines
which participate in the recruitment not only of inflam-
matory cells (neutrophils and macrophages), but also
fibroblasts and endothelial cells. The second stage of
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wound healing is the proliferative phase. Active angio-
genesis which is critical for the wound healing process,
allows new capillaries to deliver nutrients including oxy-
gen to the wound, and contributes to the proliferation of
fibroblasts. In the granulation tissue, fibroblasts become
activated and acquire a smooth muscle cell-like pheno-
type; they are consequently called myofibroblasts. These
myofibroblastic cells synthesize and deposit the extracel-
lular matrix components which will replace the provi-
sional matrix. These cells also exhibit contractile
properties, due to the expression of a-smooth muscle
actin in microfilament bundles or stress fibers, playing a
major role in the contraction and in maturation of the
granulation tissue [4] (Figure 1). Presently, it is accepted
that the myofibroblastic modulation of fibroblastic cells
begins with the appearance of the protomyofibroblast,
whose stress fibers contain only b- and g-cytoplasmic
actins. Protomyofibroblasts evolve in most cases into dif-
ferentiated myofibroblasts, the most common variant of
this cell, with stress fibers containing a-smooth muscle
actin (for review, see [5]) (Figure 1). Myofibroblasts can,
depending on the experimental or clinical situation,
express other smooth muscle cell specific contractile pro-
teins, such as smooth muscle-myosin heavy chains or
desmin; however, the presence of a-smooth muscle actin
represents the most reliable marker of the myofibroblastic
phenotype [6]. The third phase of healing, scar formation,
involves a progressive remodelling of the granulation tis-
sue. During this remodelling process, proteolytic enzymes,
essentially matrix metalloproteinases (MMPs) and their
inhibitors (TIMPs for tissue inhibitor of metalloprotei-
nases) play a major role [7]. In the resolution phase of
healing, the cell number of vascular cells and myofibro-
blasts is dramatically reduced by the process of apoptosis
[8] (Figure 1). To date, it has not been clearly shown that
myofibroblasts can reacquire a quiescent phenotype.
Pathological repair
Pathological wound healing can be encountered in a vari-
ety of disease states [9]. These abnormal repair processes
are the result of an impaired remodelling of the granula-
tion tissue leading for example to abnormal cutaneous
repair as seen in hypertrophic scarring or to fibrosis in
internal organs such as the liver, lung and kidney. In
hypertrophic scars, numerous myofibroblasts express a-
smooth muscle actin, explaining the frequent appearance
of contracture [9]. In internal organs, after an acute and
moderate lesion, the injured tissue may be almost comple-
tely restored to normal. The repair process involved is
globally similar to the process observed in cutaneous
wounding. However, when the noxious stimulus responsi-
ble for the lesion persists, excessive extracellular matrix
deposition and the continued presence of myofibroblasts
is observed. This excess of extracellular matrix deposition
leads to the development of organ fibrosis. For example, in
the liver, several chronic diseases (chronic viral hepatitis,
alcoholic disease and cholestasis) are responsible for the
development of a significant fibrosis whose ultimate stage,
cirrhosis, has a substantial impact on morbidity and mor-
tality. As in pathological cutaneous wound healing, the
installation and persistence of fibrosis is the consequence
of an imbalance between extracellular matrix synthesis
and degradation by myofibroblasts. In this situation the
balance of MMPs/TIMPs plays an essential role. For
example, throughout hepatic fibrogenesis, an increase of
TIMP-1 and TIMP-2 expression without any modification
of MMP-1 is observed and it is thought that this leads to
excessive matrix deposition.
Cytokines involved in myofibroblast differentiation
Various cytokines and growth factors have a role in
wound healing and scarring [10]. Among these soluble
factors some directly act on granulation tissue formation
and fibrogenic cell activation, especially transforming
growth factor (TGF)-b1, a potent inducer of myofibro-
blastic differentiation [11]. Beyond a specific effect on
Figure 1 Schematic illustration showing the evolution of the
(myo)fibroblast phenotype. The myofibroblastic modulation of
fibroblastic cells begins with the appearance of the proto-
myofibroblast, whose stress fibers contain only b- and g-cytoplasmic
actins and evolves, but not necessarily always, into the appearance
of the differentiated myofibroblast, the most common variant of this
cell, with stress fibers containing a-smooth muscle actin. The
myofibroblast may disappear by apoptosis; the deactivation leading
to a quiescent phenotype has not been clearly demonstrated at
least in vivo. TGF-b1: transforming growth factor-b1; ECM:
extracellular matrix. Modified from [38].
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the induction of a-smooth muscle expression, TGF-b1
also promotes the deposition of large amounts of extra-
cellular matrix; in fact, TGF-b1 not only induces synth-
esis of extracellular matrix, particularly fibrillar collagens
and fibronectin but it also reduces MMP activity by pro-
moting TIMP expression. It is important to note that
TGF-b1 action on myofibroblastic differentiation is only
possible in the presence of the ED-A splice variant
fibronectin which underlines the fact that extracellular
matrix components play an important role in soluble
factor activity [12]. More recently, it has been shown
that granulation tissue formation is modified by chemi-
cal denervation [13]. This peripheral nervous system
involvement in tissue repair has likewise been shown in
the liver, where in this organ, in an experimental model
of fibrosis using carbon tetrachloride treatment, chemi-
cal denervation significantly reduces matrix deposition
and myofibroblastic differentiation [14].
Role of mechanical stress
Myofibroblastic cells, because of their contractile proper-
ties and their privileged relationship with the extracellular
matrix, can modify their activity depending on the
mechanical environment. Although this is an essential
point, it still remains poorly investigated. It has been
shown, in gingival fibroblasts, that a-smooth muscle actin
expression induced by TGF-b1 is regulated by the compli-
ance of collagen gels on or in which they are cultured [15].
Moreover, myofibroblastic differentiation features, such as
stress fibers, ED-A fibronectin or a-smooth muscle
expression, appear earlier in granulation tissue subjected
to an increase in mechanical tension by splinting of a full-
thickness wound with a plastic frame as compared to nor-
mally healing wounds [16]. It has also been shown that
fibroblasts cultured on substrates of variable stiffness pre-
sent different phenotypes. Cultured fibroblasts do not
express stress fibers on soft surfaces; whilst when the stiff-
ness of the substrate increases, a sudden change in cell
morphology occurs and stress fibers appear [17,18]. More
recently, it has been shown that shear forces exerted by
fluid flow are also able to induce TGF-b1 production and
differentiation of fibroblasts cultured in collagen gels in
the absence of other external stimuli such as cytokine
treatment [19].
Origin of the myofibroblast
Myofibroblasts can originate from various cell types as
illustrated in Figure 2. The major contribution of the cells
originates from local recruitment of connective tissue
fibroblasts. For example in the skin, dermal fibroblasts
located at the edges of the wound can acquire a myofibro-
blastic phenotype and participate in tissue repair. In the
liver, the role of perisinusoidal hepatic stellate cells has
been widely studied and their key role during fibrogenesis
has been clearly demonstrated. However, in the connective
tissue, important heterogeneity in fibroblastic cell subpo-
pulations has been observed. These subpopulations reside
in different locations within the organ and have specific
activation and deactivation properties. At least three sub-
populations have been identified in the dermis: superficial
dermal fibroblasts, reticular fibroblasts, which reside in the
deep dermis, and fibroblasts associated with hair follicles.
These cell subpopulations can be isolated and exhibit dis-
tinctive differences when cultured separately [20]. In the
liver, in the main two subpopulations of fibrogenic cells
have been described: i) the hepatic stellate cells located in
the space of Disse between the hepatocytes and the sinu-
soidal endothelial cells and ii) the portal fibroblasts located
in the connective tissue surrounding portal tracts [21]. We
recently applied the precision cut-liver slice (PCLS) model
which preserves the normal lobular architecture and
allows the maintenance of cell-cell interactions within
their original extracellular matrix to study hepatic stellate
cell and portal fibroblast behaviour in rat PCLS derived
from fibrotic tissue [22,23]. In pathological situations,
myofibroblastic cells expressing a-smooth muscle actin
are derived either from hepatic stellate cells (e.g. in alco-
holic cirrhosis where myofibroblasts are present in the
parenchyma and in septa) or from portal fibroblasts (e.g.
in cholestatic fibrosis where myofibroblasts are present in
enlarged portal areas). Thus, in the liver, fibrogenic cells
mainly include hepatic stellate cells and portal fibroblasts,
even if, in some cases, second layer cells located around
centrilobular veins can be involved in parenchymal fibrosis
[24]. Moreover, today, the involvement in tissue repair of
Figure 2 Myofibroblast origins . The main myofibroblast
progenitor after injury of different tissues appears to be locally
residing fibroblasts. Indeed, various cell types can acquire a
myofibroblastic phenotype; these diverse origins lead to distinct
myofibroblast sub-populations. EMT: epithelial- and endothelial-to-
mesenchymal transition.
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local mesenchymal stem cells is discussed more and more.
These progenitor cells have been described in the dermal
sheath that surrounds the outside of the hair follicle facing
the epithelial stem cells. They are involved in the regenera-
tion of the dermal papilla and they can also became
wound healing (myo)fibroblasts after a lesion [25].
Mesenchymal stem cells have not yet been described in
the liver, but at the periphery of portal tracts, in Hering’s
canals, epithelial stem cells have been described. Hering’s
canal represents the junction between hepatocytes and
bile duct epithelial cells, and in this area, numerous prolif-
erative cells are observed after a hepatic lesion. This area
may constitute a niche containing not only epithelial stem
cells but also mesenchymal stem cells and these two cell
types may cooperate depending on the tissue need. This
concept of a cell association, able to reconstitute the differ-
ent organ cell populations and constituting a niche of stem
cells is currently discussed in diverse organs notably in the
liver [26]. Recent data have also implicated circulating
cells, called fibrocytes, in the tissue repair process. Fibro-
cytes enter into injured skin together with inflammatory
cells and acquire a myofibroblastic phenotype [27]. In
post-burn scars, fibrocytes are recruited to the site of the
lesion where they stimulate local inflammatory response
and produce extracellular matrix proteins thus contribut-
ing to hypertrophic scar formation [28]. Fibrocytes are
also implicated in the lung in subepithelial fibrosis
observed in asthma [29], and in renal fibrosis [30].
Another type of circulating cell originating from bone
marrow has been suggested to participate in tissue repair.
These mesenchymal stem cells are bone marrow-derived
non-hematopoietic precursor cells [31] that contribute to
the maintenance and regeneration of connective tissues
through engraftment. Indeed, they have the capacity to
engraft into several organs and to differentiate into wound
healing myofibroblasts. The engraftment in injured organs
is regulated by the severity of the damage [32]. Interest-
ingly, very poor engraftment of intravenously administered
mesenchymal stem cells in healthy organs was observed.
In hepatic fibrosis, a significant proportion of myofibro-
blasts may originate from the bone marrow [33]. Finally,
epithelial- and endothelial-to-mesenchymal transition
(EMT), a process by which differentiated or malignant
epithelial and endothelial cells undergo a phenotypic con-
version that gives rise to the matrix-producing fibroblasts
and myofibroblasts, is increasingly recognized as an inte-
gral part of tissue fibrogenesis after injury, particularly in
the kidney [34]. However, the degree to which this process
contributes to fibrosis remains a matter of intense debate
and is likely to be context-dependent. All together,
mesenchymal stem cells, fibrocytes, bone marrow-derived
cells and cells derived from an EMT process, may repre-
sent alternative sources of myofibroblasts when local
fibroblasts are not able to satisfy the tissue’s requirement
for these cells.
Conclusions and perspectives
The fibroblast/myofibroblast transition is accepted as the
key event in the formation of granulation tissue during
wound healing or fibrotic changes, but also during the
evolution of the stroma reaction in cancer. Though differ-
ent experimental models have been developed, until now,
the exact origin of the (myo)fibroblastic cells involved in
the formation of the stroma reaction observed in carcino-
mas is unknown. Obviously, local fibroblasts present in
the connective tissue of the organ are involved. However,
it has also been shown that bone marrow-derived myofi-
broblasts contribute to the stroma reaction [35,36]. Inter-
estingly, the question arises as to why the stroma reaction
is scanty in hepatocellular carcinoma but abundant in cho-
langiocarcinoma. It is conceivable that the cells contribut-
ing to the myofibroblastic population and which
participate in the stroma reaction are different in these
two tumors. We suggest that hepatic stellate cell-derived
myofibroblasts and portal fibroblast-derived myofibro-
blasts are involved in the stroma reactions encountered in
hepatocellular carcinoma and cholangiocarcinoma, respec-
tively, and we have recently performed a proteomic study
in order to make progress in this field [37]. All of this
information is required for the development of treatments
that could specifically and efficiently target the cells
responsible for the development of fibrotic diseases and of
the stroma reaction in cancers. Indeed, stroma-myofibro-
blast interactions represent an interesting tumor differen-
tiation-independent target for therapy of cancers,
particularly for hepatocellular carcinoma and cholangio-
carcinoma which are highly aggressive cancers.
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